{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for abametapir in Reference Text / Citation (approximate match)
Showing 1 - 1 of 1 results
Status:
US Previously Marketed
Source:
XEGLYZE by HATCHTECH
(2020)
Source URL:
First approved in 2020
Source:
XEGLYZE by HATCHTECH
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Abametapir is a newly FDA-approved, single-application treatment for head lice in patients aged 6 months and older. Abametapir chelates heavy metal cations and inhibits metalloproteinases critical to louse ova development, hatching, and adult survival. Abametapir lotion, 0.74%, demonstrated significant ovicidal activity against head lice eggs with a single application.
